Sufiya Z Safina

Sufiya Z Safina

Auto-generated profile, based on publicly available information

Sufiya Z Safina

Republican Dispensary of Tatarstan, 420029 Kazan, Russia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
ANA.K. Nurgalieva
A.K. Nurgalieva
Vladimir PopovVladimir Popov
Vladimir Popov
VSVera Skripova
Vera Skripova
LBLeisan Bulatova
Leisan Bulatova
DSD.V. Savenkova
D.V. Savenkova
Ramziya KiyamovaRamziya Kiyamova
Ramziya Kiyamova
The high mortality rate from ovarian cancer is due to the asymptomatic nature of the course of the disease, which leads to the diagnosis of ovarian cancer in later stages. The sodium-dependent phosphate transporter NaPi2b encoded by SLC34A2 gene is expressed in 80–90% of epithelial ovarian cancers and used as a target for therapeutic antibodies XMT-1536, and XMT-1592, which are derived from MX35 antibodies and used in clinical trials for the treatment of ovarian and lung cancers. In this work, we aimed to evaluate NaPi2b as a molecular marker for diagnostics and predicting the course and outcome of ovarian cancer disease.

27 December 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
Ilya V. TsimafeyeuIlya V. Tsimafeyeu
Ilya V. Tsimafeyeu
VCViacheslav Chubenko
Viacheslav Chubenko
OBOlga Baklanova
Olga Baklanova
AKAlexey Kalpinskiy
Alexey Kalpinskiy
SSSufia Safina
Sufia Safina
RORashida Orlova
Rashida Orlova
Background: The RAVE-Renal study was conducted to evaluate the real-world efficacy and safety of avelumab plus axitinib as a first-line therapy for patients with metastatic renal cell carcinoma (mRCC). Methods: RAVE-Renal was a multicenter, noninterventional, ambispective study with both retrospective and prospective components. The study included adult patients with histologically confirmed mRCC, measurable disease per RECIST version 1.1, and no prior systemic therapy. Patients received avelumab (800 mg intravenously every 2 weeks) plus axitinib (5 mg orally twice daily). The primary endpoints were median progression-free survival (PFS) and objective response rate (ORR). The secondary endpoints included median OS, 1-year overall survival (OS) rate, and safety. Results: A total of 125 patients from 13 sites were enrolled, with a median follow-up of 16.1 months. The median age was 61.0 years. The study population comprised 35.3% favorable, 49% intermediate, and 15.7% poor IMDC risk patients. The median PFS was 14.9 months (95% CI, 11.72–19.08). The ORR was 44.3% (95% CI, 32.5–56.1). The clinical benefit rate was 93.4%. The 1-year OS rate was 71.2%, with the median OS not reached. Any-grade treatment-related adverse events (TRAEs) occurred in 99 (79.2%) cases, including grade ≥3 TRAEs in 24 (19.2%). Conclusions: Avelumab in combination with axitinib showed clinical benefits in a real-world setting, consistent with findings from a pivotal trial. The regimen was effective and well tolerated across various patient subgroups.

1 January 2014 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
RBRustem F Baikeev
Rustem F Baikeev
RGRoman A Gubanov
Roman A Gubanov
KSKamil K Sadikov
Kamil K Sadikov
SSSufiya Z Safina
Sufiya Z Safina
FMFarhat F Muhamadiev
Farhat F Muhamadiev
TSTimur A Sibgatullin
Timur A Sibgatullin
The parameters that characterize the intricate water diffusion in tumors may also reveal their distinct pathology. Specifically, characterization of breast cancer could be aided by diffusion magnetic resonance.